Literature DB >> 11549783

History of quinolones and their side effects.

E Rubinstein1.   

Abstract

Fluoroquinolone development from 1985 to the present was reviewed. Severe drug adverse events were noted for enoxacin, pefloxacin and fleroxacin, which were phototoxic. Temafloxacin was associated with severe hemolytic-uremic syndrome, lomefloxacin caused phototoxicity and central nervous system (CNS) effects, and sparfloxacin was associated with phototoxicity and QTc prolongation. Tosufloxacin caused severe thrombocytopenia and nephritis, and hepatotoxicity was reported for trovafloxacin. Grepafloxacin was withdrawn due to cardiovascular effects, and clinafloxacin was associated with phototoxicity and hypoglycaemia. The structure of the quinolones directly relates to both their activity and side-effect profiles. The relationship among specific substituents attached to the quinolone nucleus are clarified. The incidence of specific adverse events associated with individual fluoroquinolones was reviewed in a five-year post-marketing surveillance (PMS) study in Japan, in which a total adverse drug reaction (ADR) rate of 1.3% was found for levofloxacin, compared to total ADR rates of 3.3% for pazufloxacin, 3.6% for tosufloxacin, 4.5% for gatifloxacin and 5.4% for balofloxacin. Gastrointestinal effects were the most common adverse events for all fluoroquinolones. Levofloxacin had the lowest rate of CNS effects and skin adverse events among the agents listed. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549783     DOI: 10.1159/000057838

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  35 in total

1.  Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.

Authors:  Alan M Hochberg; Ronald K Pearson; Donald J O'Hara; Stephanie J Reisinger
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

2.  Levofloxacin-loaded star poly(ε-caprolactone) scaffolds by additive manufacturing.

Authors:  Dario Puppi; Anna Maria Piras; Alessandro Pirosa; Stefania Sandreschi; Federica Chiellini
Journal:  J Mater Sci Mater Med       Date:  2016-01-12       Impact factor: 3.896

Review 3.  How antibiotics kill bacteria: from targets to networks.

Authors:  Michael A Kohanski; Daniel J Dwyer; James J Collins
Journal:  Nat Rev Microbiol       Date:  2010-05-04       Impact factor: 60.633

4.  Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis.

Authors:  Edgardo J Toro; Jian Zuo; David A Ostrov; Dana Catalfamo; Vivian Bradaschia-Correa; Victor Arana-Chavez; Aliana R Caridad; John K Neubert; Thomas J Wronski; Shannon M Wallet; L Shannon Holliday
Journal:  J Biol Chem       Date:  2012-04-02       Impact factor: 5.157

Review 5.  Safety profile of the fluoroquinolones: focus on levofloxacin.

Authors:  Hans H Liu
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

6.  Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

Authors:  Roberto Leone; Mauro Venegoni; Domenico Motola; Ugo Moretti; Valentina Piazzetta; Alfredo Cocci; Domenico Resi; Federico Mozzo; Giampaolo Velo; Liliana Burzilleri; Nicola Montanaro; Anita Conforti
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  Clinical trial design and selected drug safety issues for antibiotics used to treat community-acquired pneumonia.

Authors:  Bruce M Psaty
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

8.  A seizure attributed to ofloxacine in a woman undergoing detoxification for alcohol dependence.

Authors:  Pierre Lahmek; Laurent Michel; Nadine Meunier; Henri-Jean Aubin
Journal:  Case Rep Med       Date:  2010-01-24

9.  Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.

Authors:  David A Ostrov; Andrew T Magis; Thomas J Wronski; Edward K L Chan; Edgardo J Toro; Richard E Donatelli; Kristen Sajek; Ireni N Haroun; Michael I Nagib; Ana Piedrahita; Ashley Harris; L Shannon Holliday
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

10.  Fatal hypoglycemia with levofloxacin use in an elderly patient in the post-operative period.

Authors:  Madhurita Singh; Jubbin Jagan Jacob; Rajeev Kapoor; John Abraham
Journal:  Langenbecks Arch Surg       Date:  2008-01-04       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.